60 Degrees Pharmaceuticals study published in ‘New Microbes and New Infections’

60 Degrees Pharmaceuticals announced the journal, New Microbes and New Infections, has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against Candida spp. in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of Rhizopus in mice. “A substantial unmet need exists for clinical therapies that treat and prevent life-threatening fungal infections,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoffrey Dow. “Even when antifungal treatments approved by the FDA are administered to patients, the morbidity, mortality, and clinical incidence of rapidly emerging, dangerous fungal infections such as Candida and Rhizopus remain high. Data from this set of studies confirm that tafenoquine holds promise in addressing that unmet need in the U.S. It is particularly interesting that tafenoquine did not exhibit any cross-resistance to fluconazole against Candida species, and that the presumed mode of action, through the induction of oxidative stress, differs from standard of care treatments. We are pursuing this hypothesis as part of our research strategy.”